Price T Rowe Associates Inc Inhibrx, Inc. Transaction History

Price T Rowe Associates Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$32.76 - $39.56 $36,429 - $43,990	1,112 Added 8.12%	14,812 $518,000
Q4 2023 Feb 14, 2024	BUY	$14.5 - $38.0 $14,297 - $37,468	986 Added 7.76%	13,700 $521,000
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $11,072 - $18,495	703 Added 5.85%	12,714 $234,000
Q2 2023 Aug 14, 2023	BUY	$16.96 - $27.82 $203,706 - $334,146	12,011 New	12,011 $312,000

25.3K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $617M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.